Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ActiVitD trial of alfacalcidol for secondary hyperparathyroidism after Roux-en-Y gastric bypass
NL-OMON58932Phase 4Recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of alfacalcidol in secondary hyperparathyroidism (SHPT), sponsored by Leiden University Medical Center. Started Nov 2024; status: recruiting.
02
Drugs
alfacalcidol
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NL-OMON58932.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON58932.